Literature DB >> 19049712

Membranoproliferative glomerulonephritis and light-chain nephropathy in association with chronic lymphocytic leukemia.

R Mutluay1, S Zeynep Aki, Y Erten, C Konca, M Yagci, G Barit, S Sindel.   

Abstract

The incidence of nephrotic syndrome co-existing with chronic lymphocytic leukemia (CLL) is a rare condition. Almost any glomerular pathology may accompany CLL. The most frequent of all is membranoproliferative glomerulonephritis (MPGN). Moreover, in 5 - 10% of patients with CLL, monoclonal gammopathy may be detected in serum and/or urine samples. There are no well-established treatment protocols for those CLL patients with accompanying nephrotic syndrome. In this case report, we present a 55-year-old female patient diagnosed with CLL, developing nephrotic syndrome, renal dysfunction and IgG k-type monoclonal gammopathy in the follow-up. The renal biopsy revealed glomerular and tubular deposits of k-chain and histopathology of membranoproliferative glomerulonephritis. Rituximab along with CVP (cyclophosphamide - vincristine - prednisolone) chemotherapy regimen was initiated. At the end of 6 courses of treatment, the patient was on "nephrologic" partial remission as the serum creatinine and albumin levels had returned to normal and proteinuria decreased by more than 50%. The patient was also in partial remission for CLL. In conclusion, in patients with CLL and nephrotic syndrome, presence of MPGN along with light-chain nephropathy is rarely reported. Several different treatment protocols are discussed for these patients. Among these regimes, R-CVP is an acceptable alternative for CLL patients with MPGN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19049712     DOI: 10.5414/cnp70527

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  7 in total

Review 1.  Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis.

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Nat Rev Nephrol       Date:  2010-12-14       Impact factor: 28.314

Review 2.  Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-07-06

3.  Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy.

Authors:  Sanjeev Sethi; Ladan Zand; Nelson Leung; Richard J H Smith; Dragan Jevremonic; Sandra S Herrmann; Fernando C Fervenza
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

4.  Membranoproliferative Glomerulonephritis Secondary to a Low-Grade Lymphoproliferative Disorder: A Rare Cause of Renal Dysfunction.

Authors:  Tushar Sehgal; Nidhi Jain; Gaurav Prakash; Ritambhra Duseja; Neelam Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-14       Impact factor: 0.900

5.  Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.

Authors:  Paolo Strati; Samih H Nasr; Nelson Leung; Curtis A Hanson; Kari G Chaffee; Susan M Schwager; Sara J Achenbach; Timothy G Call; Sameer A Parikh; Wei Ding; Neil E Kay; Tait D Shanafelt
Journal:  Haematologica       Date:  2015-06-18       Impact factor: 9.941

6.  CLL: Common Leukemia; Uncommon Presentations.

Authors:  Deepesh Lad; Pankaj Malhotra; Neelam Varma; Manupdesh Singh Sachdeva; Ashim Das; Radhika Srinivasan; Amanjit Bal; Alka Khadwal; Gaurav Prakash; Vikas Suri; Savita Kumari; Sanjay Jain; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2014-12-24       Impact factor: 0.900

7.  A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib.

Authors:  Amy Li; Sophia L Ambruso; Ozgur Akin Oto; Marc Barry; Charles L Edelstein
Journal:  BMC Nephrol       Date:  2022-07-23       Impact factor: 2.585

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.